Aktienanalyse zu Drugs Made In America Acquisition Corp (DMAA)

KI-Analyse of Drugs Made In America Acquisition Corp (DMAA)

Halten

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Drugs Made In America Acquisition Corp (DMAA) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von 0.00.

Erwartetes KGV

Stark unterbewertet

5J-Durchschnitt P/E

0.00

Aktuelles P/E

0.00

Überbewertet

0.00

Unterbewertet

0.00

Erwartetes EV/EBITDA

Stark unterbewertet

5J-Durchschnitt EV/EBITDA

0.00

Aktuelles EV/EBITDA

0.00

Überbewertet

0.00

Unterbewertet

0.00

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

0.11

Aktuelles P/S

0.00

Überbewertet

1.18

Unterbewertet

-0.96

Alphio-AI-Kursszenarien für DMAA

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%DMAA

$10.91

Szenariopreis

B

Basis

Basis · 50%DMAA

$9.82

Szenariopreis

B

Bärisch

Bärisch · 25%DMAA

$9.57

Szenariopreis

Whales, die DMAA halten

G

Glazer Capital, LLC

+ HältDMAA

+3.19%

3-Monats-Rendite

W

Wolverine Asset Management, LLC

+ HältDMAA

-16.12%

3-Monats-Rendite

DMAA FAQ – beantwortet von Alphio AI

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.